AXL inhibitor

DRUG CLASS:

AXL inhibitor

News alerts, weekly reports and conference planners

Related drugs:

AXL positive	Non Small Cell Lung Cancer	AXL positive	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	AVB-500 Sensitive: B - Late Trials AVB-500 Sensitive : B	AVB-500 Sensitive: B - Late Trials AVB-500 Sensitive : B
AXL expression	Non Small Cell Lung Cancer	AXL expression	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria pembrolizumab + BGB324 Sensitive : C2	pembrolizumab + BGB324 Sensitive: C2 – Inclusion Criteria pembrolizumab + BGB324 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	TP-0903 Sensitive: C2 – Inclusion Criteria TP-0903 Sensitive : C2	TP-0903 Sensitive: C2 – Inclusion Criteria TP-0903 Sensitive : C2
MET mutation	Non Small Cell Lung Cancer	MET mutation	Non Small Cell Lung Cancer	MGCD265 Sensitive: C2 – Inclusion Criteria MGCD265 Sensitive : C2	MGCD265 Sensitive: C2 – Inclusion Criteria MGCD265 Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	BPI-9016M Sensitive: C2 – Inclusion Criteria BPI-9016M Sensitive : C2	BPI-9016M Sensitive: C2 – Inclusion Criteria BPI-9016M Sensitive : C2
GAS6 elevation	Ovarian Cancer	GAS6 elevation	Ovarian Cancer	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3
GAS6 overexpression	Ovarian Cancer	GAS6 overexpression	Ovarian Cancer	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3
SLFN11 expression	Myelodysplastic Syndrome	SLFN11 expression	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
ANG elevation	Myelodysplastic Syndrome	ANG elevation	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
AXL elevation	Myelodysplastic Syndrome	AXL elevation	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
SLFN11 expression	Acute Myelogenous Leukemia	SLFN11 expression	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
ANG elevation	Acute Myelogenous Leukemia	ANG elevation	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
AXL elevation	Acute Myelogenous Leukemia	AXL elevation	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
AXL-L	HER2 Positive Breast Cancer	AXL-L	HER2 Positive Breast Cancer	trastuzumab + TP-0903 Sensitive: C3 – Early Trials trastuzumab + TP-0903 Sensitive : C3	trastuzumab + TP-0903 Sensitive: C3 – Early Trials trastuzumab + TP-0903 Sensitive : C3
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	osimertinib + TP-0903 Sensitive: C3 – Early Trials osimertinib + TP-0903 Sensitive : C3	osimertinib + TP-0903 Sensitive: C3 – Early Trials osimertinib + TP-0903 Sensitive : C3
MET exon 14 deletion	Non Small Cell Lung Cancer	MET exon 14 deletion	Non Small Cell Lung Cancer	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3
MET amplification + AXL amplification	Non Small Cell Lung Cancer	MET amplification + AXL amplification	Non Small Cell Lung Cancer	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3
MET mutation + AXL mutation	Non Small Cell Lung Cancer	MET mutation + AXL mutation	Non Small Cell Lung Cancer	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	TP-0903 Sensitive: C3 – Early Trials TP-0903 Sensitive : C3	TP-0903 Sensitive: C3 – Early Trials TP-0903 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	gefitinib + AB-329 Sensitive: C3 – Early Trials gefitinib + AB-329 Sensitive : C3	gefitinib + AB-329 Sensitive: C3 – Early Trials gefitinib + AB-329 Sensitive : C3
AXL elevation + GAS6 elevation	Clear Cell Renal Cell Carcinoma	AXL elevation + GAS6 elevation	Clear Cell Renal Cell Carcinoma	cabozantinib tablet + AVB-500 Sensitive: C3 – Early Trials cabozantinib tablet + AVB-500 Sensitive : C3	cabozantinib tablet + AVB-500 Sensitive: C3 – Early Trials cabozantinib tablet + AVB-500 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + AB-329 Sensitive: C3 – Early Trials osimertinib + AB-329 Sensitive : C3	osimertinib + AB-329 Sensitive: C3 – Early Trials osimertinib + AB-329 Sensitive : C3
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	BPI-9016M Sensitive: C3 – Early Trials BPI-9016M Sensitive : C3	BPI-9016M Sensitive: C3 – Early Trials BPI-9016M Sensitive : C3
KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3
KRAS mutation + PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation + PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3	pembrolizumab + BGB324 Sensitive: C3 – Early Trials pembrolizumab + BGB324 Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib + TP-0903 Sensitive: C4 – Case Studies osimertinib + TP-0903 Sensitive : C4	osimertinib + TP-0903 Sensitive: C4 – Case Studies osimertinib + TP-0903 Sensitive : C4
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	JRF104 Sensitive: D – Preclinical JRF104 Sensitive : D	JRF104 Sensitive: D – Preclinical JRF104 Sensitive : D
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D	BGB324 Sensitive: D – Preclinical BGB324 Sensitive : D

AXL inhibitor

AXL inhibitor

Associations(58)

Associations
(58)